--- title: AbbVie (ABBV) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/abbv ticker: ABBV as_of: 2026-10-17 sector: Healthcare industry: Drug Manufacturers - General --- # AbbVie (ABBV) AbbVie (ABBV) closed at $285.42 on Oct 16, 2026, right at its model value of $286.71 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $285.42 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $286.71 | | Price vs model | at model value | | Range of that model | $161.76 – $724.81 | | Market value | $504.4B | | P/E (fiscal 2025) | 120.9 | | Net margin (fiscal 2025) | 6.9% | | Free cash flow (fiscal 2025) | $17.8B | | Dividend yield (trailing twelve months) | 2.42% | | Beta | 0.28 | | Cost of capital (WACC) | 6.77% | | Business classification | Dividend Payer (Low/slowing growth (~6% recent), Moderate margins (7% net margin), Pays dividends, Highly cyclical earnings, High leverage (D/E 5.0x)) | ## On the stock lists | List | Place | Figure | Page | | --- | ---: | ---: | --- | | Largest companies | #21 | $504.4B | https://sweetvaluelab.com/lists/largest-companies | | Near 52-week highs | #12 | 0.0% | https://sweetvaluelab.com/lists/near-52-week-highs | ## Dividends | Figure | Value | | --- | ---: | | Trailing dividend yield | 2.42% | | Dividends per share, last 12 months | $6.92 | | Dividends / free cash flow (fiscal 2025) | 65.4% | | Raised | 12+ years in a row | | Growth over 5 years | 5.9% a year | | Latest payment | $1.73, ex-date Oct 15, 2026, paid Nov 16, 2026 | | Year of payments | Dividends per share | | --- | ---: | | To Oct 14, 2021 | $5.20 | | To Oct 13, 2022 | $5.64 | | To Oct 12, 2023 | $5.92 | | To Oct 15, 2024 | $6.20 | | To Oct 15, 2025 | $6.56 | | Trailing twelve months (to Oct 15, 2026) | $6.92 | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $286.71 | $161.76 | $724.81 | | DCF · Perpetuity growth · 10y | cross check | $300.21 | $175.76 | $741.88 | | DCF · EBITDA exit · 5y | cross check | $230.79 | $160.43 | $313.74 | | DCF · EBITDA exit · 10y | cross check | $252.43 | $174.72 | $355.87 | | P/E · peers | cross check | $173.85 | $151.94 | $285.44 | | P/E · own history | cross check | $502.82 | $187.98 | $695.09 | | PEG | sanity check | $347.95 | $347.95 | $347.95 | | EV/EBITDA · peers | cross check | $185.07 | $138.57 | $309.50 | | EV/Revenue · peers | cross check | $193.02 | $142.83 | $346.11 | | Earnings power value | cross check | $75.87 | $55.73 | $107.48 | | Dividend discount | cross check | $186.90 | $119.84 | $356.37 | ## Insider activity (SEC Form 4) Past 90 days: 0 open-market buys ($0) and 1 open-market sale ($8.2M); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 30, 2026 | Quaggin Susan E | Director | Grant / award | 59 | $15,433.8 | | Sep 30, 2026 | RAPP EDWARD J | Director | Grant / award | 129 | $33,745.1 | | Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Open-market sell | 32,710 | $8.2M | | Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Option/RSU exercise | 32,710 | $0 | | Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Option/RSU exercise | 32,710 | $2.6M | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Oct 15, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/1551152/000110465926116227/tm2627361d1_8k.htm | | Oct 5, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1551152/000155115226000030/abbv-20261005.htm | | Sep 3, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm | | Aug 18, 2026 | 8-K | 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1551152/000110465926098367/tm2623337d1_8k.htm | | Aug 6, 2026 | 424B5 | Prospectus supplement | https://www.sec.gov/Archives/edgar/data/1551152/000110465926092114/tm2621452-3_424b5.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Torray | 2026-06-30 | 82,602 | $20.8M | | Mairs & Power | 2026-06-30 | 44,702 | $11.2M | | David Katz | 2026-09-30 | 33,896 | $8.9M | | Thomas Russo | 2026-06-30 | 12,410 | $3.1M | 8 tracked managers in all. ## About AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREO… --- Source: https://sweetvaluelab.com/stocks/abbv (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.